Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer(Başkent University), Saadettin Kılıçkap(Hacettepe University Hospital), Mahmut Gümüş(Istanbul Medeniyet University), Igor Bondarenko(Dnipropetrovsk State Medical Academy), Mustafa Özgüroğlu(Istanbul University-Cerrahpaşa), Miranda Gogishvili, Hacı Mehmet Türk(Bezmiâlem Vakıf Üniversitesi), İrfan Çiçin(Trakya University), Dmitry Bentsion(Ulyanovsk Regional Oncology Center), Oleg Gladkov, Philip R. Clingan(Illawarra Health and Medical Research Institute), Virote Sriuranpong(King Chulalongkorn Memorial Hospital), Naiyer A. Rizvi(Columbia University Irving Medical Center), Bo Gao(Regeneron (United States)), Siyu Li(Regeneron (United States)), Sue Lee(Regeneron (United States)), Kristina McGuire(Regeneron (United States)), Chieh-I Chen(Regeneron (United States)), Tamta Makharadze, Semra Paydaş(Cukurova University), Marina Nechaeva(International Institute of Management Arkhangelsk), Frank Seebach(Regeneron (United States)), David M. Weinreich(Regeneron (United States)), George D. Yancopoulos(Regeneron (United States)), Giuseppe Gullo(Regeneron (United States)), Israel Lowy(Regeneron (United States)), Petra Rietschel(Regeneron (United States))
Cited by 794
Abstract
Related Papers
No related papers found
Powered by citation graph analysis